Report error Found 101 of ic50 data for polymerid = 50006699
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 136nMAssay Description:Inhibition of BAZ2A (unknown origin) after 30 mins by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 160nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 316nMAssay Description:Inhibition of BAZ2A (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 400nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 550nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 580nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 720nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 880nMAssay Description:Binding affinity to human partial length BAZ2A expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 880nMAssay Description:Binding affinity to human partial length BAZ2A expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 890nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.10E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.20E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.20E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.40E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.50E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.70E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.80E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.80E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.30E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 4.00E+3nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 4.10E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 4.10E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 6.31E+3nMAssay Description:Inhibition of BAZ2A (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 7.20E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 8.60E+3nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human BAZ2A (M1792 to L1905 residues) expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human BAZ2A (M1792 to L1905 residues) expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.00E+4nMAssay Description:Inhibition of human BAZ2A (M1792 to L1905 residues) expressed in bacterial expression system by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.06E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.09E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.10E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.10E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.14E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.18E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.25E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.26E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.29E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.31E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.40E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 1.41E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.20E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.51E+4nMAssay Description:Inhibition of BAZ2A (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.51E+4nMAssay Description:Inhibition of BAZ2A (unknown origin) by TR-FRET assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 2.92E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.00E+4nMAssay Description:Inhibition of recombinant His6-TEV fused human BAZ2A expressed in Escherichia coli incubated for 30 mins in presence of biotinylated peptide by alpha...More data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.13E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.16E+4nMAssay Description:Inhibition of human BAZ2A by BROMOscan assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.32E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
TargetBromodomain adjacent to zinc finger domain protein 2A(Human)
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Cancer Research Uk Cancer Therapeutics Unit
Curated by ChEMBL
Affinity DataIC50: 3.32E+4nMAssay Description:Inhibition of His6-tagged BAZ2A (unknown origin) (1796 to 1899 residues) using H3K(Ac)14 substrate by AlphaScreen assayMore data for this Ligand-Target Pair
